EGMN -- Patients with moderate to severe systolic heart failure and an elevated heart rate had a marked drop in their rate of heart failure death and hospitalization when they were treated with the heart-rate–lowering drug ivabradine in a phase III, randomized trial with more than 6,500 patients.
